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Background: : Healthcare workers (HCWs) have increased rates of SARS-CoV-2 infection compared with the
general population. We aimed to understand ethnic differences in SARS-CoV-2 seropositivity among hospital
healthcare workers depending on their hospital role, socioeconomic status, Covid-19 symptoms and basic
demographics.
Methods: A prospective longitudinal observational cohort study. 1364 HCWs at five UK hospitals were stud-
ied with up to 16 weeks of symptom questionnaires and antibody testing (to both nucleocapsid and spike
protein) during the first UK wave in five NHS hospitals between March 20 and July 10 2020. The main out-
come measures were SARS-CoV-2 infection (seropositivity at any time-point) and symptoms. Registration
number: NCT04318314.
Findings: 272 of 1364 HCWs (mean age 40.7 years, 72% female, 74% White, 6 samples per participant) sero-
converted, reporting predominantly mild or no symptoms. Seropositivity was lower in Intensive Therapy
Unit (ITU) workers (OR=0.44 95%CI 0.24, 0.77; p=0.0035). Seropositivity was higher in Black (compared to
White) participants, independent of age, sex, role and index of multiple deprivation (OR=2.61 95%CI 1.47-
4.62 p=0.0009). No association was seen betweenWhite HCWs and other minority ethnic groups.
Interpretation: In the UK first wave, Black ethnicity (but not other ethnicities) more than doubled HCWs like-
lihood of seropositivity, independent of age, sex, measured socio-economic factors and hospital role.
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Ethnic differences in severe disease hospitalisation [1] andmortality
[2] emerged early in the SARS-CoV-2 pandemic. Proposed explanations
include the impact of comorbidities, genetic and socio-economic fac-
tors, including access to healthcare, personal protective (PPE) equip-
ment, behavioural and occupational influences [3]. However, most
SARS-CoV-2 infections are non-hospitalised with approximately one-
third asymptomatic [4]. Large-scale community cross-sectional epide-
miological studies have reported higher infection prevalence in certain
ethnic minority populations [5]. These studies however typically report
PCR tests in symptomatic individuals or single time point community
surveillance [6], underestimating true case ascertainment. Even for
population serology studies at scale, limitations remain including recall
bias (for symptoms), reduced test sensitivity or specificity (PCR/antigen
testing especially at point-of-care), variable/inappropriate timing of
tests (prior to sero-conversion; after sero-reversion) and challenges
with adjusting for exposure and socio-economic status.
Frontline healthcare workers (HCWs) are at higher SARS-CoV-2
infection risk [7,8,9] with reported estimates from 3.4 to 18 times higher
than the general population [810]. Understanding HCW infection is
important. Nosocomial transmission can make hospitals pandemic
amplifiers/sustainers [11] and lessons from the first wave are swiftly
needed as subsequent waves emerge. HCWs are also work-force repre-
sentative, easier to study (e.g. during lock-down), have good ethnic
minority representation [5,12] and have many societal socio-economic
and behavioural confounders removed or measurable (by NHS role),
making them useful to explore ethnic differences in SARS-CoV-2 trans-
mission dynamics. Finally, working in an environment where there is
substantial risk of sustained exposure, HCW cohort studies allow an
assessment of the impact of mitigation strategies such as PPE [13].
Using best available technology to define SARS-CoV-2 infection
and symptoms (longitudinal data collection, multi-timepoint accu-
rate lab-based antibody assays for two antigens), this study assessed
differences in symptomatology, serological prevalence and infection
severity in HCWs by ethnicity across five hospitals, correcting for
demographic and socio-economic differences where feasible.
Methods
Healthcare worker cohorts
A five hospital HCW longitudinal study (n=1,364) of UK first wave
SARS-CoV-2 infection consisting of two initially independent studies
A.M. Valdes et al. / EClinicalMedicine 34 (2021) 100835 3(PANTHER, Nottingham: Nottingham City Hospital and Queen’s Med-
ical Centre - both Nottingham University Hospital NHS trust; COVID-
sortium, London: St Bartholomew’s, Nightingale and Royal Free
Hospitals) that were methodologically aligned for scale in April 2020
(NCT04318314). London ethical approval was South Central - Oxford
A Research Ethics Committee, reference 20/SC/0149. Nottingham was
initially under a Human Tissue Authority licence in Nottingham
(Licence number: 11035) and subsequently also North West - Greater
Manchester South Research Ethics Committee, reference 20/NW/
0395. All participants provided written informed consent prior to
completing the questionnaire and providing blood samples.
Both studies recruited asymptomatic HCWs attending work.
Nurses, doctors, allied health professionals and other frontline
health-care workers were recruited in Nottingham and London, with
additional staff from other workforce groups (hospital administrative
staff, porters and cleaners) in London. Both studies started early in
their local pandemic waves (23rd March 2020, London  day one of
first UK lockdown20 April in Nottingham) Results presented here.
Data included in this study refers to weekly or fortnightly serolog-
ical and symptoms data up to 10 July 2020. Data was stored in MS
Access databases, C Manisty, J Moon A Valdes had access to the data
collected in London, J Nightingale, B Ollivere, A Valdes had access to
the data collected in Nottingham with sample collection and detailed
questionnaires (demographics including self-declared ethnicity split
as white of any origin (British white, Irish white, or white of any other
origin), Black [both African or Caribbean], South Asian, East Asian,
mixed, other), occupational roles and ward type, comorbidities,
travel, exposure, PPE, symptoms). Participants attended for follow-up
if asymptomatic and working; those with symptoms or in self-isola-
tion resumed on return to work, supplying prior symptoms with
minimal delay to reduce recall bias. Further study details are pub-
lished elsewhere [14,15]. Blood serum samples for serological assess-
ment were immediately spun and stored at -80°C. Both studies
collected information on hospital role, age, gender and body mass
index.
Anti-S1 and anti-nucleocapsid assays
Both studies performed serial SARS-CoV-2 serology testing assess-
ing antibodies to both spike (S1) and nucleocapsid protein (NP).
The London samples were analysed using validated commercial
assays; the Euroimmun anti-SARS-CoV-2 enzyme-linked immuno-
sorbent assay (ELISA) targeting IgG specific for S1 [16], and the Roche
Elecsys Anti-SARS-CoV-2 electrochemiluminescence immunoassay
(ECLIA) that detects antibodies (including IgG) for N protein [17].
These were undertaken at the Rare & Imported Pathogens Laboratory
at Public Health England using standard protocols, total 12,990 tests.
Positive was defined as (Euroimmun) a ratio of sample OD to calibra-
tor OD >1.1, and (Roche) a electrochemiluminescence sample to lot-
specific cutoff index >1, as per manufacturers’ instructions. Reported
assay sensitivity (92.3% and 96.2%-100% for Roche and Euroimmune
respectively) and specificities (100%) are high [18,19].
The Nottingham study used in-house ELISA robotically delivered
assays cross-validated by the same Public Health England laboratory
(Porton-Down, UK). Assay details are in supplementary methods. In
brief, they were ELISAs to S1 and N protein detecting immunoglobu-
lin G. Individuals were classified as seropositive if they had a positive
titre to either protein at any time point. Seropositivity was defined as
samples where the average measurement of the duplicates exceeded
two-times the median value for the pooled negative controls.
Symptoms
Individuals were classified as having case-definition symptoms, if
at any time point they reported characteristic symptoms (fever, dry
cough, loss of sense of smell or taste) using the symptoms-basedmodel developed previously [20], or if they had to self-isolate due to
symptoms of COVID-19. Individuals were classified as asymptomatic
if they either did not report any symptoms or reported symptoms
not matching the case definition (i.e. the clinical criteria for assessing
possibility of infection with COVID-19 based on characteristic symp-
toms).
Statistical analysis
Associations between seropositivity and demographic, social or
hospital roles were assessed by standard logistic regression, adjusting
for all available covariates. Missing or unspecified data was imputed
to the mean value. Where missing data was more than 10% sub-anal-
yses were run only on individuals who had the trait with and without
adjustment Because of potential differences in serological assays
between London and Nottingham, results were not pooled. Rather,
fixed effects meta-analyses were performed on odds ratios and stan-
dard error estimates derived from the logistic regressions. The het-
erogeneity variance was computed for each meta analysis and where
it was t2>0.10 a DerSimonian Laird random effects estimate was
used. All analyses were carried out using R version 3.6.1 (2019-07-
05) (The R Foundation for Statistical Computing).
Socio-economic confounders adjustment
We assigned each participant based on their postcode, the Index
of Multiple Deprivation (IMD) decile for their geographical area. The
English IMD, the official measure of relative deprivation in England,
follows an established methodological framework in broadly defining
deprivation to encompass a wide range of an individual’s living con-
ditions [21]. This area-based measure of deprivation is derived from
ranking the 32,844 Lower Layer Super Output Areas (LSOAs, the geo-
graphic unit used by the Office of National statistics) in England and
dividing them into deciles.
Role of funding source
The funding bodies had no role in study design, data collection, or
analysis of the data.
Results
The descriptive characteristics of both HCW cohorts are presented
in Table 1 and individual cohorts have been previously
described.14,15 In short, mean age across the combined cohorts was
40.7 years, SD,11.6, range 18-69, and 71.6% female. The ethnic mix of
the cohort was 73.5% of White, 4.3% Black ethnicity, 9.4% South Asian,
5.7% East Asian, 6.2% other or mixed. This is a similar proportion of
ethnic minorities as in the NHS at large (26.3 vs 22.1% in the NHS [12]
and a slightly lower proportion of women (71.6%) compared with
77% in the NHS at large [22].
The average number of antibody tests was 10 paired samples for
each London HCW and 6.5 for each Nottingham HCW. 21.3% of Lon-
don HCWs (157 out of 731) and 18.2% of Nottingham HCWs (115 out
of 633) were seropositive denoting infection, with no significant dif-
ference between both cities overall (P=0.071). Infections were pre-
dominantly mild, with two participants (one of White ethnicity, one
of East Asian) being hospitalised briefly, but with no requirement for
ventilation and no deaths. Of the 272 participants seropositive at any
time point, 24.8% participants reported case-definition symptoms at
the time of or in the two months preceding seroconversion (i.e. sero-
positivity), and the remainder reported either atypical symptoms or
were entirely asymptomatic. Typical symptoms were strongly associ-
ated with seropositivity (OR= 3.66 (2.73, 4.90) p=1£10[-18]);
Figure 1).
Table 1
Rates of SARS-CoV-2 seropositivity (IgGs against either nucleocapsid or spike 1 proteins) among healthcare workers from five
hospitals. Individuals were assessed over a 13 (London) or 10 (Nottingham) week period between 23 March 2020 and 10 July
2020 and are considered seropositive if they showed seropositivity at any time point during this longitudinal assessment.
London Nottingham
Ab- Ab+ Seropositive% Ab- Ab+ Seropositive%
Hospital City Hospital 165 37 18.3%
QMC 353 78 17.9%
Barts/Nightingale 403 101 20.0%
Royal Free 171 56 24.7%
Total 574 157 21.5% 518 115 18.2%
Age Mean years 37.8 39.4 43.1 43.9
(SD) 10.9 11 11.6 11.6
BMI Mean kg/m2 25.0 25.6 26.5 26.9
(SD) 4.5 4.4 4.8 5.0
Sex M 188 54 22.3% 115 22 16.1%
F 384 102 21.0% 401 93 18.7%
Other/Unspec 2 1 33.3% 2 0 0.0%
Case definition* Yes 111 71 39.0% 108 42 28.0%
Covid-19 No 463 86 15.7% 410 73 15.1%
symptoms
Ethnicity Asian 126 25 16.6% 46 12 20.7%
South Asian 67 12 15.2% 40 10 20.0%
East Asian 57 13 18.6% 6 2 25.0%
OtherAsian 1 2
Black 24 18 42.9% 10 7 41.2%
Other/Mixed 46 6 11.5% 24 9 27.3%
Unspecified 6 1 14.3% 1 0
White 372 107 22.3% 439 87 16.5%
IMD decile 1-3 138 46 25.0% 98 29 22.8%
4-7 265 76 22.3% 177 38 17.7%
8-10 73 21 22.3% 130 29 18.2%
Unspecified 98 14 12.5% 113 19 14.4%
Use of PPE ITU role 109 17 13.5% 36 1 2.7%
use PPE not ITU 353 112 24.1% 337 84 20.0%
other roles 112 28 20.0% 147 30 16.9%
Hospital role Doctor 115 35 23.3% 68 20 22.7%
Nurse/AHP 386 98 20.2% 312 67 17.7%
Clinical Support worker 7 3 30.0% 10 1 9.1%
other 67 20 23.0% 128 27 17.4%
ITU= intensive therapy unit; AHP = allied healthcare professional; clinical support worker includes portering and cleaning
staff
* the clinical criteria for assessing possibility of infection with COVID-19 based on characteristic symptoms
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(42%) than of White HCWs (19%) (adj OR=2.61 (1.47, 4.62) p=0.0009),
however there were no significant associations between seropositiv-
ity and ethnicity when South Asian, East Asian or mixed/other non-
Black minority ethnic groups were compared to White HCWs
(Figure 1). Although we saw higher seropositivity among East Asian
HCW in Nottingham, this result is derived from a very small sample
size (n=8) and is not observed in the larger London cohort which
includes n=70 East Asian HCWs. No significant association was seen
with regards to other/mixed ethnicity (OR= 0.81 95%CI 0.42, 1.57
n.s.).
There were no associations of seropositivity with age, BMI (OR=
1.01;95%CI 0.98-1.05), sex, IMD and use of PPE outside of an intensive
therapy unit (ITU), (Figure 1). However, HCWs who had an ITU role
had half the likelihood of being seropositive (OR=0.44 95%CI 0.24,
0.77; p=0.0035). No other significant differences in infection rates
were found between different hospital roles (doctors compared with
nurses and other allied healthcare professionals, or clinical support
and administrative staff; Table 1).
Even after adjusting for other confounders (demographics, occu-
pation and IMD), the association of increased risk of infection with
Black ethnicity remained significant (OR=2.61 95%CI 1.47-4.62p=0.0009) (Figure 1). Across seropositive HCWs, there were no differ-
ences in timing of infection (with potential for recall bias) by ethnic-
ity, or in antibody responses to infection, with similar durations of
seropositivity, and peak antibody responses between different ethnic
groups. The association between Black ethnicity and symptomatic
infection (OR=2.57 95%CI 1.20-5.09 p=0.0167) and between Black
ethnicity and asymptomatic infection (OR=3.20 95%CI 1.64-6.22
p=0.0006) in the two HCW cohorts are similar therefore we find no
evidence for this association between Black ethnicity and seropositiv-
ity being in any way linked to the presence or absence of Covid-19
symptoms.
Finally, because IMD was missing for 17.8% of individuals we car-
ried out sensitivity analyses only on participants who had complete
data. The significant associations of seropositivity with Black ethnic-
ity (OR= 2.61 95% CI 1.47, 4.62), ITU role (OR= 0.43 95%CI 0.24, 0.76)
and Covid-19 symptoms (random effects OR=3.39 95% CI 1.36,8.46)
were extremely similar to those including imputed IMD data.
Discussion
These data show that, after adjusting for demographic and socio-
economic confounders and levels of exposure at work, Black HCWs
Figure 1. Association between SARS-COV-2 seropositivity over a 10-13 week period and demographic, hospital role and ethnicity in 1365 healthcare workers from London and Not-
tingham. All analyses are adjusted for age (per year), sex (male vs female), body mass index, index of multiple deprivation (IMD, per decile), hospital role (ITU vs non ITU, doctors vs
other roles), presence of symptoms and ethnicity (vs Whites). Where the heterogeneity variance (t2) is equal to 0 the fixed effect meta-analysis estimates are the same as random
effects . Where t2 >0 Dersimonian-Laird random effects estimates (indicated as Summary RE) are presented; .p-values shown for results that are statistically significant with
p<0.05.
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6 A.M. Valdes et al. / EClinicalMedicine 34 (2021) 100835are at higher likelihood of seropositivity to SARS-CoV-2 than of White
HCWs. By studying HCWs across five hospitals with weekly symptom
and serological assessment using two assays, case ascertainment was
robust and the risk of either symptom recall bias or false positive or
negative serological testing was minimised. Investigating a hospital
HCW cohort with broad representation across different employment
roles partially corrects for differences in exposure, socio-economic
status, use of protective equipment and body mass index between
ethnic groups, which was further addressed by adjusting for IMD.
Multiple previous studies have highlighted higher rates of hospi-
talisation for SARS-COV-2 infection across different BAME groups
than would be expected from local demographics [1,23], with worse
outcomes in hospitalised COVID-19 patients [2]. More recently epide-
miological studies using primary care data (the largest including data
from over 17.5 million people across the UK) have shown higher rates
of test positivity for SARS-COV-2 in Black [24,5], as well as Asian and
other ethnic minority groupings. All of the studies using retrospective
analysis of routinely-collected healthcare record data are however
subject to bias from ethnic differences in access to testing and health-
care alongside co-morbidities, reducing the accuracy of ascertain-
ment of ‘true’ rates of infection. Better assessments of population
infection rates can be obtained from large-scale prospective epidemi-
ological studies with surveillance serology testing, with UK data from
the REACT-2 study [4] using lateral flow immunoassay IgG to SARS-
COV-2 finding point seroprevalence rates of 17.3% in people of Black
ethnicity, although differentiating biological from socio-economic
explanations behind these differences is challenging [25,26,27].
Our data, which have not explored differences in severity but only
in seropositivity, do not exclude that socio-economic factors and in
particular, health inequalities and higher rates of cardiometabolic or
pulmonary comorbidities lead to the increased incidence and severity
of SARS-CoV-2 infection (hospitalisations and mortality) observed in
certain ethnic minority groups [28].
A potential study limitation was that the prevalence of specific
comorbidities which was not included in the analysis. This was due
to the different way these were collected in the two cohorts making a
meaningful meta-analysis difficult to carry out. However, in each
individual cohort no significant association between seroprevalence
over the 10-13 weeks of observation and individual comorbidities
was observed. Moreover, we find no association with BMI which is
strongly correlated with most cardiometabolic and respiratory
comorbidities (Table 1), therefore this is unlikely to have biased our
results.
The reasons for increased rates of infection among Black HCWs
may represent a combination of behavioural and biological factors.
However, the lack of independent association with socioeconomic
and other surrogates of behavioural confounding suggests a role for
biological factors. This in turn suggests ethnic/heritable differences in
resistance or protective immunity that may ultimately provide direct
correlates of adaptive response to infection or vaccine mediated pro-
tection. Differences in innate immunity between individuals of Euro-
pean and African descent have been described and the functional
genetic variations identified [29]. Moreover, differences in adaptive
immune response have also been reported [30] specifically in the
context of response to vaccination. Such data combined with ours
suggests that individuals from some ethnic groups may be more
likely to mount an antibody response to an asymptomatic or pauci-
symptomatic infection where individuals with a different genetic or
ethnic background may use an innate immune response at the same
level of exposure.
Future studies regarding the duration of neutralizing antibodies in
different ethnic groups are necessary. The study failed to find differ-
ences in seropositivity across other ethnic minority groups, and point
to the fact that the different rates of severe disease and mortality
observed among Asians cannot be explained by increased rates of
infection. It is likely that, independent of risk of infection, comorbidconditions and socio-economic factors likely play the main role in the
higher susceptibility to a more severe form of Covid-19 among Asians
[31]. This highlights the importance of disaggregating broad ethnic
groupings such as BAME to better understand [6,32 root causes
behind ethnic differences [24].
We further confirm the clear protective effect of working in ITU
compared with other roles [6] during the first wave of the pandemic,
with no differences seen between other occupational roles (doctors,
nurses and allied healthcare professionals or clinical support staff),
including front-line roles with responsibility for patients with
COVID-19. This provides confidence in the validity of our data and
suggests that the early prioritisation of higher grades of PPE to ITU
staff [33], alongside differences in behaviours (social distancing and
hand hygiene) [34,35] offered effective protection against nosocomial
infections, and that such measures on subsequent waves could
achieve similar protection for all staff.
There are several strengths of the current study. The seropreva-
lence data reflects five hospitals in two regions of the UK, and covers
seropositivity over a period of 3 months during the first wave of the
pandemic. The cohort had high exposure to SARS-CoV-2 and low inci-
dence of co-morbidities. The study was prospective with weekly
serial testing enabling understanding of infection timing and provid-
ing confidence in accuracy of overall infection and seroconversion
rates over the period of study (rather than point prevalence). We
have been able to adjust for confounders such as socioeconomic sta-
tus and hospital role, location, (which one of the key determinants of
differences in severity of Covid-19) [36] and contemporaneous col-
lection of symptom data (rather than retrospective collection used in
other studies) [32] improved confidence in symptom correlation
with infection and reduced recall bias. We also note some study limi-
tations. The data reported here focuses on mild (pauci-symptomatic)
and asymptomatic infections and does not touch on the important
issue of higher mortality and severity observed among HCWs belong-
ing to ethnic minorities during the pandemic. This however has
enabled us to focus on transmission at what is expected to be a rela-
tively homogenous exposure level, and minimises the impact of
health behaviours or access to care. Moreover, we have due to sample
size constraints been unable to investigate links between atypical
symptoms and seropositivity. Across both cohorts, classification of
ethnic minority grouping was self-reported. Categories were broad -
this may hide potential biological impacts (for example between Afri-
can versus Caribbean participants), however larger studies would be
needed to address this comprehensively. The current study included
59 participants of self-reported Black ethnicity and therefore further
studies on larger sample sizes will also be required to confirm gener-
alisability of the current findings to the general population.
Rates of seroconversion to SARS-CoV-2 are higher in healthcare
workers of Black ethnicity compared with their White colleagues,
even after adjustment for age, sex, socio-economic status and occu-
pational role. This difference was not present for HCWs from other
ethnic minority groups. These results support biological explanations
for differences in asymptomatic and paucisymptomatic response to
SARS-CoV-2 infection between different ethnic groups, and warrant
further study, particularly in light of vaccine-mediated protection.Authors’ contributions
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